Personal information

No personal information available

Activities

Employment (4)

Albert Einstein College of Medicine, Yeshiva University: NY, NY, US

2021-08-02 to present | Graduate Student (Systems and Computational Biology)
Employment
Source: Self-asserted source
Christopher McClain

Icahn School of Medicine at Mount Sinai: New York, NY, US

2017-08-22 to 2021-08-02 | Associate Researcher II (Hematology/Oncology)
Employment
Source: Self-asserted source
Christopher McClain

Hera Biolabs: Lexington, KY, US

2016-08-22 to 2017-08-12 | Research Technician
Employment
Source: Self-asserted source
Christopher McClain

Charles River Laboratories: Ashland, OH, US

2014-09-25 to 2016-08-20 | Research Technician II (Toxicology)
Employment
Source: Self-asserted source
Christopher McClain

Works (19)

Data from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Data from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Fig 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Fig 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Fig 2 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Fig 2 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Fig 3 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Fig 3 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Figure Legend from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Figure Legend from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Table 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

Supplementary Table 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

2023-04-04 | Preprint
Contributors: Anna Pavlick; Ana B. Blazquez; Marcia Meseck; Michael Lattanzi; Patrick A. Ott; Thomas U. Marron; Rose Marie Holman; John Mandeli; Andres M. Salazar; Christopher B. McClain et al.
Source: check_circle
Crossref

MMP2 and TLRs modulate immune responses in the tumor microenvironment

JCI Insight
2021-06-22 | Journal article
Contributors: Luciana R. Muniz-Bongers; Christopher B. McClain; Mansi Saxena; Gerold Bongers; Miriam Merad; Nina Bhardwaj
Source: check_circle
Crossref

Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors

Cell
2020-11 | Journal article
Part of ISSN: 0092-8674
Source: Self-asserted source
Christopher McClain

The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies

PLOS ONE
2020-10-07 | Journal article
Part of ISSN: 1932-6203
Source: Self-asserted source
Christopher McClain

SARS-CoV-2: the many pros of targeting PLpro

Signal Transduction and Targeted Therapy
2020-10-06 | Journal article
Contributors: Christopher B. McClain; Nicolas Vabret
Source: check_circle
Crossref

Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients

Cancer Immunology Research
2019-11-07 | Journal article
Part of ISSN: 2326-6066
Part of ISSN: 2326-6074
Source: Self-asserted source
Christopher McClain
grade
Preferred source (of 2)‎

Y-RNAs Lead an Endogenous Program of RIG-I Agonism Mobilized upon RNA Virus Infection and Targeted by HIV

[]
2019-09-18 | Preprint
Source: Self-asserted source
Christopher McClain

Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts

Molecular Cancer Therapeutics
2018-11 | Journal article
Part of ISSN: 1535-7163
Part of ISSN: 1538-8514
Source: Self-asserted source
Christopher McClain